Kahn Brothers Group Inc. DE Has $15.63 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Kahn Brothers Group Inc. DE decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 309,537 shares of the medical equipment provider’s stock after selling 30,165 shares during the quarter. Hologic makes up approximately 2.0% of Kahn Brothers Group Inc. DE’s holdings, making the stock its 15th largest holding. Kahn Brothers Group Inc. DE owned about 0.12% of Hologic worth $15,629,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of HOLX. Price T Rowe Associates Inc. MD raised its position in shares of Hologic by 0.3% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 42,197,163 shares of the medical equipment provider’s stock valued at $2,026,308,000 after acquiring an additional 116,925 shares during the last quarter. BlackRock Inc. raised its position in shares of Hologic by 0.5% during the 2nd quarter. BlackRock Inc. now owns 18,609,553 shares of the medical equipment provider’s stock valued at $893,630,000 after acquiring an additional 95,737 shares during the last quarter. Parnassus Investments CA raised its position in shares of Hologic by 1.9% during the 3rd quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock valued at $799,048,000 after acquiring an additional 300,090 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of Hologic by 72,308.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock valued at $254,730,000 after acquiring an additional 5,297,332 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Hologic by 5.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,043,496 shares of the medical equipment provider’s stock valued at $98,129,000 after acquiring an additional 114,554 shares during the last quarter. 95.33% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have commented on HOLX. Stifel Nicolaus upped their target price on shares of Hologic from $43.00 to $48.00 and gave the company a “hold” rating in a research report on Monday, August 5th. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and upped their target price for the company from $54.00 to $59.00 in a research report on Thursday, September 26th. BTIG Research reiterated a “buy” rating and set a $52.00 target price on shares of Hologic in a research report on Thursday, August 1st. Argus upped their target price on shares of Hologic to $62.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Piper Jaffray Companies upped their target price on shares of Hologic from $49.00 to $59.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Hologic currently has a consensus rating of “Hold” and a consensus target price of $51.48.

Shares of HOLX traded up $0.36 during trading hours on Friday, reaching $46.56. The stock had a trading volume of 2,274,912 shares, compared to its average volume of 1,801,817. The company has a quick ratio of 1.11, a current ratio of 1.57 and a debt-to-equity ratio of 1.27. Hologic, Inc. has a 52 week low of $37.48 and a 52 week high of $52.19. The firm has a 50-day moving average of $48.95 and a 200 day moving average of $47.99. The company has a market cap of $12.86 billion, a P/E ratio of 20.30, a P/E/G ratio of 2.03 and a beta of 0.76.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.65. The firm had revenue of $865.80 million during the quarter, compared to analysts’ expectations of $846.54 million. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.58 EPS. As a group, equities analysts expect that Hologic, Inc. will post 2.64 earnings per share for the current year.

In other Hologic news, insider Peter J. Valenti III sold 7,766 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $49.14, for a total transaction of $381,621.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.90% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: Can individual investors take part in an IPO?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply